BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Úbeda M, Lario M, Muñoz L, Borrero MJ, Rodríguez-Serrano M, Sánchez-Díaz AM, Del Campo R, Lledó L, Pastor Ó, García-Bermejo L, Díaz D, Álvarez-Mon M, Albillos A. Obeticholic acid reduces bacterial translocation and inhibits intestinal inflammation in cirrhotic rats. J Hepatol 2016;64:1049-57. [PMID: 26723896 DOI: 10.1016/j.jhep.2015.12.010] [Cited by in Crossref: 80] [Cited by in F6Publishing: 75] [Article Influence: 11.4] [Reference Citation Analysis]
Number Citing Articles
1 Arab JP, Martin-Mateos RM, Shah VH. Gut-liver axis, cirrhosis and portal hypertension: the chicken and the egg. Hepatol Int. 2018;12:24-33. [PMID: 28550391 DOI: 10.1007/s12072-017-9798-x] [Cited by in Crossref: 58] [Cited by in F6Publishing: 53] [Article Influence: 11.6] [Reference Citation Analysis]
2 Hullar MAJ, Jenkins IC, Randolph TW, Curtis KR, Monroe KR, Ernst T, Shepherd JA, Stram DO, Cheng I, Kristal BS, Wilkens LR, Franke A, Le Marchand L, Lim U, Lampe JW. Associations of the gut microbiome with hepatic adiposity in the Multiethnic Cohort Adiposity Phenotype Study. Gut Microbes 2021;13:1965463. [PMID: 34491886 DOI: 10.1080/19490976.2021.1965463] [Reference Citation Analysis]
3 Wu W, Liu L, Zhu H, Sun Y, Wu Y, Liao H, Gui Y, Li L, Liu L, Sun F, Lin H. Butyrolactone-I, an efficient α-glucosidase inhibitor, improves type 2 diabetes with potent TNF-α-lowering properties through modulating gut microbiota in db/db mice. FASEB J 2019;33:12616-29. [PMID: 31450982 DOI: 10.1096/fj.201901061R] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
4 Albhaisi SAM, Bajaj JS. The Influence of the Microbiome on NAFLD and NASH. Clin Liver Dis (Hoboken) 2021;17:15-8. [PMID: 33552480 DOI: 10.1002/cld.1010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
5 Anderson KM, Gayer CP. The Pathophysiology of Farnesoid X Receptor (FXR) in the GI Tract: Inflammation, Barrier Function and Innate Immunity. Cells 2021;10:3206. [PMID: 34831429 DOI: 10.3390/cells10113206] [Reference Citation Analysis]
6 Xiong X, Ren Y, Cui Y, Li R, Wang C, Zhang Y. Obeticholic acid protects mice against lipopolysaccharide-induced liver injury and inflammation. Biomed Pharmacother. 2017;96:1292-1298. [PMID: 29174575 DOI: 10.1016/j.biopha.2017.11.083] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
7 Mouries J, Brescia P, Silvestri A, Spadoni I, Sorribas M, Wiest R, Mileti E, Galbiati M, Invernizzi P, Adorini L, Penna G, Rescigno M. Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development. J Hepatol. 2019;71:1216-1228. [PMID: 31419514 DOI: 10.1016/j.jhep.2019.08.005] [Cited by in Crossref: 103] [Cited by in F6Publishing: 107] [Article Influence: 34.3] [Reference Citation Analysis]
8 Juanola O, Piñero P, Gómez-Hurtado I, Caparrós E, García-Villalba R, Marín A, Zapater P, Tarín F, González-Navajas JM, Tomás-Barberán FA, Francés R. Regulatory T Cells Restrict Permeability to Bacterial Antigen Translocation and Preserve Short-Chain Fatty Acids in Experimental Cirrhosis. Hepatol Commun 2018;2:1610-23. [PMID: 30556045 DOI: 10.1002/hep4.1268] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
9 Simbrunner B, Trauner M, Reiberger T. Review article: therapeutic aspects of bile acid signalling in the gut-liver axis. Aliment Pharmacol Ther 2021;54:1243-62. [PMID: 34555862 DOI: 10.1111/apt.16602] [Reference Citation Analysis]
10 Jin HS, Kim TS, Jo EK. Emerging roles of orphan nuclear receptors in regulation of innate immunity. Arch Pharm Res 2016;39:1491-502. [PMID: 27699647 DOI: 10.1007/s12272-016-0841-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
11 Gitto S, Guarneri V, Sartini A, Andreone P. The use of obeticholic acid for the management of non-viral liver disease: current clinical practice and future perspectives. Expert Rev Gastroenterol Hepatol 2018;12:165-71. [PMID: 29082798 DOI: 10.1080/17474124.2018.1399060] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
12 Shimozato N, Namisaki T, Kaji K, Kitade M, Okura Y, Sato S, Moriya K, Seki K, Kawaratani H, Takaya H, Sawada Y, Saikawa S, Nakanishi K, Furukawa M, Fujinaga Y, Kubo T, Asada K, Kitagawa K, Tsuji Y, Kaya D, Ozutsumi T, Akahane T, Mitoro A, Yoshiji H. Combined effect of a farnesoid X receptor agonist and dipeptidyl peptidase-4 inhibitor on hepatic fibrosis. Hepatol Res 2019;49:1147-61. [PMID: 31177586 DOI: 10.1111/hepr.13385] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
13 Pierantonelli I, Svegliati-baroni G. Nonalcoholic Fatty Liver Disease: Basic Pathogenetic Mechanisms in the Progression From NAFLD to NASH. Transplantation 2019;103:e1-e13. [DOI: 10.1097/tp.0000000000002480] [Cited by in Crossref: 73] [Cited by in F6Publishing: 50] [Article Influence: 24.3] [Reference Citation Analysis]
14 Verbeke L, Mannaerts I, Schierwagen R, Govaere O, Klein S, Vander Elst I, Windmolders P, Farre R, Wenes M, Mazzone M, Nevens F, van Grunsven LA, Trebicka J, Laleman W. FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis. Sci Rep. 2016;6:33453. [PMID: 27634375 DOI: 10.1038/srep33453] [Cited by in Crossref: 105] [Cited by in F6Publishing: 98] [Article Influence: 17.5] [Reference Citation Analysis]
15 Wan SZ, Liu C, Huang CK, Luo FY, Zhu X. Ursolic Acid Improves Intestinal Damage and Bacterial Dysbiosis in Liver Fibrosis Mice. Front Pharmacol 2019;10:1321. [PMID: 31736766 DOI: 10.3389/fphar.2019.01321] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
16 Chen YH, Hu XG, Zhou Y, Yu Z, Fu L, Zhang GB, Bo QL, Wang H, Zhang C, Xu DX. Obeticholic Acid Protects against Lipopolysaccharide-Induced Fetal Death and Intrauterine Growth Restriction through Its Anti-Inflammatory Activity. J Immunol 2016;197:4762-70. [PMID: 27821667 DOI: 10.4049/jimmunol.1601331] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
17 Deniz CD, Ozler S, Sayın FK. Association of adverse outcomes of intrahepatic cholestasis of pregnancy with zonulin levels. Journal of Obstetrics and Gynaecology 2021;41:904-9. [DOI: 10.1080/01443615.2020.1820463] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
18 Yan K, Hung A, Parmer C, Yang H, Jain D, Lim B, Goodman AL, Garcia-Tsao G. Obeticholic Acid Decreases Intestinal Content of Enterococcus in Rats With Cirrhosis and Ascites. Hepatol Commun 2021;5:1507-17. [PMID: 34510838 DOI: 10.1002/hep4.1740] [Reference Citation Analysis]
19 Hao F, Guo H, Zhong J, Geng Q, Yang Y, Chen B, Guo C. Effects of Prostaglandin E1 on Patients Undergoing Major Gastrointestinal Surgery. Ann Surg 2018;267:759-65. [PMID: 28121679 DOI: 10.1097/SLA.0000000000002152] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
20 Williams B, Ghosh M, Boucher CAB, Bushman F, Carrington-Lawrence S, Collman RG, Dandekar S, Dang Q, Malaspina A, Paredes R, Wilson CC, Nowak P, Klatt NR, Lagenaur L, Landay AL. A Summary of the Second Annual HIV Microbiome Workshop. AIDS Res Hum Retroviruses 2017;33:1258-64. [PMID: 28899105 DOI: 10.1089/aid.2017.0137] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
21 Friedman ES, Li Y, Shen TD, Jiang J, Chau L, Adorini L, Babakhani F, Edwards J, Shapiro D, Zhao C, Carr RM, Bittinger K, Li H, Wu GD. FXR-Dependent Modulation of the Human Small Intestinal Microbiome by the Bile Acid Derivative Obeticholic Acid. Gastroenterology. 2018;155:1741-1752.e5. [PMID: 30144429 DOI: 10.1053/j.gastro.2018.08.022] [Cited by in Crossref: 40] [Cited by in F6Publishing: 43] [Article Influence: 10.0] [Reference Citation Analysis]
22 Arroyo V, Moreau R, Kamath PS, Jalan R, Ginès P, Nevens F, Fernández J, To U, García-Tsao G, Schnabl B. Acute-on-chronic liver failure in cirrhosis. Nat Rev Dis Primers 2016;2:16041. [PMID: 27277335 DOI: 10.1038/nrdp.2016.41] [Cited by in Crossref: 159] [Cited by in F6Publishing: 144] [Article Influence: 26.5] [Reference Citation Analysis]
23 Bloom PP, Tapper EB, Young VB, Lok AS. Microbiome therapeutics for hepatic encephalopathy. J Hepatol 2021;75:1452-64. [PMID: 34453966 DOI: 10.1016/j.jhep.2021.08.004] [Reference Citation Analysis]
24 Wang K, Bao L, Zhou N, Zhang J, Liao M, Zheng Z, Wang Y, Liu C, Wang J, Wang L, Wang W, Liu S, Liu H. Structural Modification of Natural Product Ganomycin I Leading to Discovery of a α-Glucosidase and HMG-CoA Reductase Dual Inhibitor Improving Obesity and Metabolic Dysfunction in Vivo. J Med Chem 2018;61:3609-25. [DOI: 10.1021/acs.jmedchem.8b00107] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 6.5] [Reference Citation Analysis]
25 Simbrunner B, Mandorfer M, Trauner M, Reiberger T. Gut-liver axis signaling in portal hypertension. World J Gastroenterol 2019; 25(39): 5897-5917 [PMID: 31660028 DOI: 10.3748/wjg.v25.i39.5897] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 19] [Article Influence: 8.7] [Reference Citation Analysis]
26 Fukui H. Leaky Gut and Gut-Liver Axis in Liver Cirrhosis: Clinical Studies Update. Gut Liver 2021;15:666-76. [PMID: 33071239 DOI: 10.5009/gnl20032] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
27 Namisaki T, Moriya K, Kitade M, Takeda K, Kaji K, Okura Y, Shimozato N, Sato S, Nishimura N, Seki K, Kawaratani H, Takaya H, Sawada Y, Akahane T, Saikawa S, Nakanishi K, Kubo T, Furukawa M, Noguchi R, Asada K, Kitagawa K, Ozutsumi T, Tsuji Y, Kaya D, Fujinaga Y, Yoshiji H. Effect of combined farnesoid X receptor agonist and angiotensin II type 1 receptor blocker on hepatic fibrosis. Hepatol Commun 2017;1:928-45. [PMID: 29404501 DOI: 10.1002/hep4.1104] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
28 Xiao Y, Wang Y, Liu Y, Wang W, Tian X, Chen S, Lu Y, Du J, Cai W. A nonbile acid farnesoid X receptor agonist tropifexor potently inhibits cholestatic liver injury and fibrosis by modulating the gut-liver axis. Liver Int 2021;41:2117-31. [PMID: 33894097 DOI: 10.1111/liv.14906] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Tang WHW, Bäckhed F, Landmesser U, Hazen SL. Intestinal Microbiota in Cardiovascular Health and Disease: JACC State-of-the-Art Review. J Am Coll Cardiol 2019;73:2089-105. [PMID: 31023434 DOI: 10.1016/j.jacc.2019.03.024] [Cited by in Crossref: 111] [Cited by in F6Publishing: 107] [Article Influence: 55.5] [Reference Citation Analysis]
30 Roehlen N, Crouchet E, Baumert TF. Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives. Cells 2020;9:E875. [PMID: 32260126 DOI: 10.3390/cells9040875] [Cited by in Crossref: 49] [Cited by in F6Publishing: 50] [Article Influence: 24.5] [Reference Citation Analysis]
31 Smeuninx B, Boslem E, Febbraio MA. Current and Future Treatments in the Fight Against Non-Alcoholic Fatty Liver Disease. Cancers (Basel) 2020;12:E1714. [PMID: 32605253 DOI: 10.3390/cancers12071714] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
32 Schwabl P, Laleman W. Novel treatment options for portal hypertension. Gastroenterol Rep (Oxf). 2017;5:90-103. [PMID: 28533907 DOI: 10.1093/gastro/gox011] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 3.4] [Reference Citation Analysis]
33 Lange CM, Moreau R. Immunodysfunction in Acute-on-Chronic Liver Failure. Visc Med 2018;34:276-82. [PMID: 30345285 DOI: 10.1159/000488690] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
34 Wiest R, Albillos A, Trauner M, Bajaj JS, Jalan R. Targeting the gut-liver axis in liver disease. J Hepatol. 2017;67:1084-1103. [PMID: 28526488 DOI: 10.1016/j.jhep.2017.05.007] [Cited by in Crossref: 163] [Cited by in F6Publishing: 151] [Article Influence: 32.6] [Reference Citation Analysis]
35 Muñoz L, Borrero MJ, Úbeda M, Conde E, Del Campo R, Rodríguez-Serrano M, Lario M, Sánchez-Díaz AM, Pastor O, Díaz D, García-Bermejo L, Monserrat J, Álvarez-Mon M, Albillos A. Intestinal Immune Dysregulation Driven by Dysbiosis Promotes Barrier Disruption and Bacterial Translocation in Rats With Cirrhosis. Hepatology 2019;70:925-38. [PMID: 30414342 DOI: 10.1002/hep.30349] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 12.3] [Reference Citation Analysis]
36 Wu W, Lv L, Shi D, Ye J, Fang D, Guo F, Li Y, He X, Li L. Protective Effect of Akkermansia muciniphila against Immune-Mediated Liver Injury in a Mouse Model. Front Microbiol. 2017;8:1804. [PMID: 29033903 DOI: 10.3389/fmicb.2017.01804] [Cited by in Crossref: 71] [Cited by in F6Publishing: 67] [Article Influence: 14.2] [Reference Citation Analysis]
37 Szabo G, Petrasek J. Gut-liver axis and sterile signals in the development of alcoholic liver disease. Alcohol Alcohol 2017;52:414-24. [PMID: 28482064 DOI: 10.1093/alcalc/agx025] [Cited by in Crossref: 32] [Cited by in F6Publishing: 24] [Article Influence: 8.0] [Reference Citation Analysis]
38 Ortega-Ribera M, Hunt NJ, Gracia-Sancho J, Cogger VC. The Hepatic Sinusoid in Aging and Disease: Update and Advances From the 20th Liver Sinusoid Meeting. Hepatol Commun 2020;4:1087-98. [PMID: 32626839 DOI: 10.1002/hep4.1517] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
39 Shi D, Lv L, Fang D, Wu W, Hu C, Xu L, Chen Y, Guo J, Hu X, Li A, Guo F, Ye J, Li Y, Andayani D, Li L. Administration of Lactobacillus salivarius LI01 or Pediococcus pentosaceus LI05 prevents CCl4-induced liver cirrhosis by protecting the intestinal barrier in rats. Sci Rep 2017;7:6927. [PMID: 28761060 DOI: 10.1038/s41598-017-07091-1] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 6.2] [Reference Citation Analysis]
40 Singh S, Osna NA, Kharbanda KK. Treatment options for alcoholic and non-alcoholic fatty liver disease: A review. World J Gastroenterol 2017; 23(36): 6549-6570 [PMID: 29085205 DOI: 10.3748/wjg.v23.i36.6549] [Cited by in CrossRef: 81] [Cited by in F6Publishing: 65] [Article Influence: 16.2] [Reference Citation Analysis]
41 Chi ZC. Intestinal microbiome and autoimmune liver disease. Shijie Huaren Xiaohua Zazhi 2019; 27(1): 50-62 [DOI: 10.11569/wcjd.v27.i1.50] [Reference Citation Analysis]
42 Voiosu A, Wiese S, Voiosu T, Bendtsen F, Møller S. Bile acids and cardiovascular function in cirrhosis. Liver Int 2017;37:1420-30. [DOI: 10.1111/liv.13394] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 3.4] [Reference Citation Analysis]
43 Verbeke L, Nevens F, Laleman W. Steroidal or non-steroidal FXR agonists – Is that the question? Journal of Hepatology 2017;66:680-1. [DOI: 10.1016/j.jhep.2017.01.013] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
44 Inoue T, Nakayama J, Moriya K, Kawaratani H, Momoda R, Ito K, Iio E, Nojiri S, Fujiwara K, Yoneda M, Yoshiji H, Tanaka Y. Gut Dysbiosis Associated With Hepatitis C Virus Infection.Clin Infect Dis. 2018;67:869-877. [PMID: 29718124 DOI: 10.1093/cid/ciy205] [Cited by in Crossref: 70] [Cited by in F6Publishing: 70] [Article Influence: 23.3] [Reference Citation Analysis]
45 Van der Merwe S, Chokshi S, Bernsmeier C, Albillos A. The multifactorial mechanisms of bacterial infection in decompensated cirrhosis. J Hepatol 2021;75 Suppl 1:S82-S100. [PMID: 34039494 DOI: 10.1016/j.jhep.2020.11.029] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
46 Floreani A, De Martin S, Ikeura T, Okazaki K, Gershwin ME. Gut microbial profiling as a therapeutic and diagnostic target for managing primary biliary cholangitis. Expert Opinion on Orphan Drugs 2020;8:507-14. [DOI: 10.1080/21678707.2020.1865917] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
47 Wang W, Zhao J, Gui W, Sun D, Dai H, Xiao L, Chu H, Du F, Zhu Q, Schnabl B, Huang K, Yang L, Hou X. Tauroursodeoxycholic acid inhibits intestinal inflammation and barrier disruption in mice with non-alcoholic fatty liver disease.Br J Pharmacol. 2018;175:469-484. [PMID: 29139555 DOI: 10.1111/bph.14095] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 8.3] [Reference Citation Analysis]
48 Brescia P, Rescigno M. The gut vascular barrier: a new player in the gut-liver-brain axis. Trends Mol Med 2021:S1471-4914(21)00154-4. [PMID: 34229973 DOI: 10.1016/j.molmed.2021.06.007] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
49 Iwakiri Y, Trebicka J. Portal hypertension in cirrhosis: Pathophysiological mechanisms and therapy. JHEP Rep 2021;3:100316. [PMID: 34337369 DOI: 10.1016/j.jhepr.2021.100316] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
50 Dawson PA. Bile Formation and the Enterohepatic Circulation. Physiology of the Gastrointestinal Tract. Elsevier; 2018. pp. 931-56. [DOI: 10.1016/b978-0-12-809954-4.00041-4] [Cited by in Crossref: 6] [Article Influence: 1.5] [Reference Citation Analysis]
51 Fianchi F, Liguori A, Gasbarrini A, Grieco A, Miele L. Nonalcoholic Fatty Liver Disease (NAFLD) as Model of Gut-Liver Axis Interaction: From Pathophysiology to Potential Target of Treatment for Personalized Therapy. Int J Mol Sci 2021;22:6485. [PMID: 34204274 DOI: 10.3390/ijms22126485] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
52 Bernardi M, Caraceni P. Novel perspectives in the management of decompensated cirrhosis. Nat Rev Gastroenterol Hepatol 2018;15:753-64. [DOI: 10.1038/s41575-018-0045-2] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 6.0] [Reference Citation Analysis]
53 Mohandas S, Vairappan B. Ginkgolide-A attenuates bacterial translocation through activating PXR and improving antimicrobial peptide Reg 3A in experimental cirrhosis. Life Sciences 2020;257:118111. [DOI: 10.1016/j.lfs.2020.118111] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
54 Schwabl P, Hambruch E, Seeland BA, Hayden H, Wagner M, Garnys L, Strobel B, Schubert TL, Riedl F, Mitteregger D, Burnet M, Starlinger P, Oberhuber G, Deuschle U, Rohr-Udilova N, Podesser BK, Peck-Radosavljevic M, Reiberger T, Kremoser C, Trauner M. The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction. J Hepatol. 2017;66:724-733. [PMID: 27993716 DOI: 10.1016/j.jhep.2016.12.005] [Cited by in Crossref: 71] [Cited by in F6Publishing: 67] [Article Influence: 11.8] [Reference Citation Analysis]
55 Hendrikx T, Schnabl B. Antimicrobial proteins: intestinal guards to protect against liver disease. J Gastroenterol 2019;54:209-17. [PMID: 30392013 DOI: 10.1007/s00535-018-1521-8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
56 Trebicka J, Macnaughtan J, Schnabl B, Shawcross DL, Bajaj JS. The microbiota in cirrhosis and its role in hepatic decompensation. J Hepatol 2021;75 Suppl 1:S67-81. [PMID: 34039493 DOI: 10.1016/j.jhep.2020.11.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
57 Li B, Selmi C, Tang R, Gershwin ME, Ma X. The microbiome and autoimmunity: a paradigm from the gut-liver axis. Cell Mol Immunol 2018;15:595-609. [PMID: 29706647 DOI: 10.1038/cmi.2018.7] [Cited by in Crossref: 73] [Cited by in F6Publishing: 67] [Article Influence: 18.3] [Reference Citation Analysis]
58 Tawfiq RA, Nassar NN, Hammam OA, Allam RM, Elmazar MM, Abdallah DM, Attia YM. Obeticholic acid orchestrates the crosstalk between ileal autophagy and tight junctions in non-alcoholic steatohepatitis: Role of TLR4/TGF-β1 axis. Chemico-Biological Interactions 2022. [DOI: 10.1016/j.cbi.2022.109953] [Reference Citation Analysis]
59 Aguirre Valadez JM, Rivera-Espinosa L, Méndez-Guerrero O, Chávez-Pacheco JL, García Juárez I, Torre A. Intestinal permeability in a patient with liver cirrhosis. Ther Clin Risk Manag 2016;12:1729-48. [PMID: 27920543 DOI: 10.2147/TCRM.S115902] [Cited by in Crossref: 23] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
60 Yu LX, Schwabe RF. The gut microbiome and liver cancer: mechanisms and clinical translation. Nat Rev Gastroenterol Hepatol 2017;14:527-39. [PMID: 28676707 DOI: 10.1038/nrgastro.2017.72] [Cited by in Crossref: 176] [Cited by in F6Publishing: 168] [Article Influence: 35.2] [Reference Citation Analysis]
61 Legry V, Francque S, Haas JT, Verrijken A, Caron S, Chávez-Talavera O, Vallez E, Vonghia L, Dirinck E, Verhaegen A, Kouach M, Lestavel S, Lefebvre P, Van Gaal L, Tailleux A, Paumelle R, Staels B. Bile Acid Alterations Are Associated With Insulin Resistance, but Not With NASH, in Obese Subjects. J Clin Endocrinol Metab 2017;102:3783-94. [PMID: 28938455 DOI: 10.1210/jc.2017-01397] [Cited by in Crossref: 44] [Cited by in F6Publishing: 44] [Article Influence: 8.8] [Reference Citation Analysis]
62 Flynn CR, Albaugh VL, Abumrad NN. Metabolic Effects of Bile Acids: Potential Role in Bariatric Surgery. Cell Mol Gastroenterol Hepatol 2019;8:235-46. [PMID: 31075353 DOI: 10.1016/j.jcmgh.2019.04.014] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
63 Liu Y, Xiao Y, Chen S, Tian X, Wang W, Wang Y, Cai W. The Farnesoid X Receptor Agonist Tropifexor Prevents Liver Damage in Parenteral Nutrition-fed Neonatal Piglets. J Pediatr Gastroenterol Nutr 2021;73:e11-9. [PMID: 33783400 DOI: 10.1097/MPG.0000000000003135] [Reference Citation Analysis]
64 Hegyi P, Maléth J, Walters JR, Hofmann AF, Keely SJ. Guts and Gall: Bile Acids in Regulation of Intestinal Epithelial Function in Health and Disease. Physiol Rev 2018;98:1983-2023. [PMID: 30067158 DOI: 10.1152/physrev.00054.2017] [Cited by in Crossref: 81] [Cited by in F6Publishing: 76] [Article Influence: 27.0] [Reference Citation Analysis]
65 Patikorn C, Veettil SK, Phisalprapa P, Pham T, Kowdley KV, Chaiyakunapruk N. Horizon scanning of therapeutic modalities for nonalcoholic steatohepatitis. Ann Hepatol 2021;24:100315. [PMID: 33515800 DOI: 10.1016/j.aohep.2021.100315] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
66 Mouzaki M, Loomba R. Insights into the evolving role of the gut microbiome in nonalcoholic fatty liver disease: rationale and prospects for therapeutic intervention. Therap Adv Gastroenterol 2019;12:1756284819858470. [PMID: 31258623 DOI: 10.1177/1756284819858470] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
67 Feng R, Ma LJ, Wang M, Liu C, Yang R, Su H, Yang Y, Wan JB. Oxidation of fish oil exacerbates alcoholic liver disease by enhancing intestinal dysbiosis in mice. Commun Biol 2020;3:481. [PMID: 32879433 DOI: 10.1038/s42003-020-01213-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
68 Kalo E, Read S, Ahlenstiel G. Targeting Gut–Liver Axis for Treatment of Liver Fibrosis and Portal Hypertension. Livers 2021;1:147-79. [DOI: 10.3390/livers1030014] [Reference Citation Analysis]
69 Morrison MC, Verschuren L, Salic K, Verheij J, Menke A, Wielinga PY, Iruarrizaga-Lejarreta M, Gole L, Yu WM, Turner S, Caspers MPM, Martínez-Arranz I, Pieterman E, Stoop R, van Koppen A, van den Hoek AM, Mato JM, Hanemaaijer R, Alonso C, Kleemann R. Obeticholic Acid Modulates Serum Metabolites and Gene Signatures Characteristic of Human NASH and Attenuates Inflammation and Fibrosis Progression in Ldlr-/-.Leiden Mice. Hepatol Commun 2018;2:1513-32. [PMID: 30556039 DOI: 10.1002/hep4.1270] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
70 Adolph TE, Grander C, Moschen AR, Tilg H. Liver–Microbiome Axis in Health and Disease. Trends in Immunology 2018;39:712-23. [DOI: 10.1016/j.it.2018.05.002] [Cited by in Crossref: 57] [Cited by in F6Publishing: 56] [Article Influence: 14.3] [Reference Citation Analysis]
71 Pataia V, McIlvride S, Papacleovoulou G, Ovadia C, McDonald JAK, Wahlström A, Jansen E, Adorini L, Shapiro D, Marchesi JR, Marschall HU, Williamson C. Obeticholic acid improves fetal bile acid profile in a mouse model of gestational hypercholanemia. Am J Physiol Gastrointest Liver Physiol 2020;319:G197-211. [PMID: 32597707 DOI: 10.1152/ajpgi.00126.2020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
72 Zhang W, Gan D, Jian J, Huang C, Luo F, Wan S, Jiang M, Wan Y, Wang A, Li B, Zhu X. Protective Effect of Ursolic Acid on the Intestinal Mucosal Barrier in a Rat Model of Liver Fibrosis. Front Physiol 2019;10:956. [PMID: 31417419 DOI: 10.3389/fphys.2019.00956] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
73 Ikegami T, Honda A. Reciprocal interactions between bile acids and gut microbiota in human liver diseases: Bile acids and gut microbiota. Hepatol Res 2018;48:15-27. [DOI: 10.1111/hepr.13001] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
74 Albillos A, de Gottardi A, Rescigno M. The gut-liver axis in liver disease: Pathophysiological basis for therapy. J Hepatol. 2020;72:558-577. [PMID: 31622696 DOI: 10.1016/j.jhep.2019.10.003] [Cited by in Crossref: 141] [Cited by in F6Publishing: 151] [Article Influence: 47.0] [Reference Citation Analysis]
75 Karthikeyan A, Mohan P, Chinnakali P, Vairappan B. Elevated systemic zonula occludens 1 is positively correlated with inflammation in cirrhosis. Clin Chim Acta. 2018;480:193-198. [PMID: 29458051 DOI: 10.1016/j.cca.2018.02.017] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
76 Albillos A, Martin-Mateos R, Van der Merwe S, Wiest R, Jalan R, Álvarez-Mon M. Cirrhosis-associated immune dysfunction. Nat Rev Gastroenterol Hepatol 2021. [PMID: 34703031 DOI: 10.1038/s41575-021-00520-7] [Reference Citation Analysis]
77 Laleman W, Trebicka J, Verbeke L. Evolving insights in the pathophysiology of complications of cirrhosis: The farnesoid X receptor (FXR) to the rescue?: Hepatology Elsewhere. Hepatology 2016;64:1792-4. [DOI: 10.1002/hep.28771] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
78 Sorribas M, Jakob MO, Yilmaz B, Li H, Stutz D, Noser Y, de Gottardi A, Moghadamrad S, Hassan M, Albillos A, Francés R, Juanola O, Spadoni I, Rescigno M, Wiest R. FXR modulates the gut-vascular barrier by regulating the entry sites for bacterial translocation in experimental cirrhosis. J Hepatol 2019;71:1126-40. [PMID: 31295531 DOI: 10.1016/j.jhep.2019.06.017] [Cited by in Crossref: 46] [Cited by in F6Publishing: 44] [Article Influence: 15.3] [Reference Citation Analysis]
79 Xu W, Nie Y, Yang Z, Lu N. The crosstalk between gut microbiota and obesity and related metabolic disorders. Future Microbiology 2016;11:825-36. [DOI: 10.2217/fmb-2015-0024] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
80 Trebicka J, Bork P, Krag A, Arumugam M. Utilizing the gut microbiome in decompensated cirrhosis and acute-on-chronic liver failure. Nat Rev Gastroenterol Hepatol 2021;18:167-80. [PMID: 33257833 DOI: 10.1038/s41575-020-00376-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
81 Namisaki T, Kaji K, Shimozato N, Kaya D, Ozutsumi T, Tsuji Y, Fujinaga Y, Kitagawa K, Furukawa M, Sato S, Sawada Y, Nishimura N, Takaya H, Okura Y, Seki K, Kawaratani H, Moriya K, Noguchi R, Asada K, Akahane T, Mitoro A, Yoshiji H. Effect of combined farnesoid X receptor agonist and angiotensin II type 1 receptor blocker on ongoing hepatic fibrosis. Indian J Gastroenterol 2022. [PMID: 35279807 DOI: 10.1007/s12664-021-01220-5] [Reference Citation Analysis]
82 Königshofer P, Brusilovskaya K, Petrenko O, Hofer BS, Schwabl P, Trauner M, Reiberger T. Nuclear Receptors in Liver Fibrosis. Biochim Biophys Acta Mol Basis Dis 2021;:166235. [PMID: 34339839 DOI: 10.1016/j.bbadis.2021.166235] [Reference Citation Analysis]
83 Albillos A, Muñoz L, Álvarez-Mon M. Reply. Hepatology 2019;69:2306-7. [PMID: 30737805 DOI: 10.1002/hep.30554] [Reference Citation Analysis]
84 Zhao X, Oduro PK, Tong W, Wang Y, Gao X, Wang Q. Therapeutic potential of natural products against atherosclerosis: Targeting on gut microbiota. Pharmacol Res 2021;163:105362. [PMID: 33285231 DOI: 10.1016/j.phrs.2020.105362] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]